Buscador de publicaciones<< Volver
Cases A, Portolés J, Calls J, Martínez-Castelao A, Munar MA, Segarra A
Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.
Int Urol Nephrol. 2014 Oct;46(10):1983-95, PMID: 25118611
To assess whether the correction dose recommended by the summary of product characteristics was adequate and to confirm the adequacy of the recommended conversion dosing strategies from shorter-acting erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator (C.E.R.A) in anaemic chronic kidney disease (CKD) patients in the clinical setting.
UROLOGY & NEPHROLOGY
Una iniciativa de
